# US 7,553,623 B2 · Method for detecting human papillomavirus mRNA

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,553,623 B2
- Document ID: US7553623B2
- Status: Granted
- Kind: B2
- Application number: 10/500,832
- Filed: 2003-01-07
- Published: 2005-06-02
- Granted: 2009-06-30
- Earliest claimed: 2002-01-07
- Assignees: Norchip A/S
- Inventors: Frank Karlsen
- Web page: https://patentgrep.com/patent/US7553623B2

## CPC

- C12Q 1/708: {for papilloma}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/16: Primer sets for multiplex assays
- Y10S 435/975: Kit
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

An in vitro method is provided for screening human female subjects to assess their risk of developing cervical carcinoma which comprises screening the subject for expression of mRNA transcripts from the E6 and optionally the L1 gene of human papillomavirus, wherein subjects positive for expression of L1 and/or E6 mRNA are scored as being at risk of developing cervical carcinoma. Kits for carrying out such methods are also provided.

## Claims

### Claim 1

An in vitro method of screening human subjects to assess their risk of developing cervical carcinoma, which method comprises screening the subject for expression of mRNA transcripts of the E6 gene of HPV types 16, 18, 31, 33 and/or 45 and sorting the subject into one of two categories of risk for development of cervical carcinoma based on expression of E6 mRNA, wherein individuals positive for expression of E6 mRNA from at least one of HPV types 16, 18, 31, 33 or 45, said positive expression being the presence of more than 50 copies of said E6 mRNA per milliliter of sample or per total volume of sample tested, are scored as carrying integrated HPV and are therefore classified as high risk for development of cervical carcinoma, whereas individuals negative for expression of E6 mRNA are scored as not carrying integrated HPV and are therefore classified as no detectable risk for development of cervical carcinoma.

### Claim 2 (depends on 1)

A method according to claim 1 wherein screening for E6 mRNA expression is carried out using an isothermal amplification method selected from the group consisting of Nucleic Acid Sequence Based Amplification (NASBA), transcription-mediated amplification, signal-mediated amplification of RNA and isothermal solution phase amplification.

### Claim 3 (depends on 2)

A method according to claim 2 wherein screening for E6 mRNA expression is carried out using real-time NASBA.

### Claim 4 (depends on 1)

A method according to claim 1 wherein the human subjects are subjects previously identified as infected with human papillomavirus DNA in cells of the cervix.

### Claim 5 (depends on 1)

A method according to claim 1 wherein the human subjects are subjects having a previous diagnosis of Atypical Squamous Cells of Undetermined Significance (ASCUS), Cervical Intraepithelial Neoplasia Grade I (CIN 1) lesions or condyloma.

### Claim 6 (depends on 1)

A method according to claim 1 which comprises screening for expression of mRNA transcripts of the E6 gene of at least one additional HPV type which is known to be prevalent in the geographical area or population under test.

### Claim 7 (depends on 1)

A method according to claim 1 which additionally comprises screening for expression of mRNA transcripts of the E6 gene of HPV type 52 and/or HPV type 58.

### Claim 8 (depends on 1)

A method according to claim 1 which comprises screening for expression of mRNA transcripts of the E6 gene of HPV types 16, 18, 31, 33 and 45.

### Claim 9 (depends on 1)

A method according to claim 1, wherein the step of sorting the subject into one of two categories of risk for development of cervical carcinoma based on expression of E6 mRNA alone.
